Susquehanna International Group’s Tonix Pharmaceuticals TNXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$407K Sell
29,579
-83
-0.3% -$1.28K ﹤0.01% 10166
2025
Q4
$463K Buy
29,662
+20,912
+239% +$386K ﹤0.01% 8974
2025
Q3
$211K Sell
8,750
-258
-3% -$9.57K ﹤0.01% 10878
2025
Q2
$324K Buy
+9,008
New +$236K ﹤0.01% 10164
2022
Q2
Hold
0
-$6K 13949
2022
Q1
Hold
0
12804
2021
Q4
Hold
0
12605
2021
Q2
Sell
-1
Closed -$1.01M 13265
2021
Q1
$1.01M Buy
+1
New +$765K ﹤0.01% 7713
2020
Q3
Hold
0
-$13K 11150
2020
Q2
Hold
0
9960
2020
Q1
Hold
0
10078
2019
Q4
Hold
0
-$11K 10647
2019
Q3
Hold
0
10011
2019
Q2
Hold
0
10041
2018
Q3
Hold
0
-$220K 10244
2018
Q2
Hold
0
8445
2017
Q4
Hold
0
-$207K 9906
2017
Q3
Hold
0
7966
2017
Q2
Hold
0
7113
2017
Q1
Hold
0
5635
2016
Q4
Hold
0
9486
2016
Q3
Hold
0
8260
2015
Q4
Hold
0
9983
2015
Q3
Hold
0
8909
2014
Q4
Hold
0
-$147K 10102
2014
Q3
Hold
0
8905

Other funds holding TNXP

Susquehanna International Group's TNXP Position: Q1 2026 in Review

Susquehanna International Group reduced its Tonix Pharmaceuticals (TNXP) stake by 0.28% in Q1 2026, selling an estimated $1.28K and leaving 29,579 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #10166.

Susquehanna International Group first reported a position in TNXP in Q1 2021 and has held it in 5 quarters since. The position peaked at $1.01M in Q1 2021. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Susquehanna International Group held 29,579 shares of Tonix Pharmaceuticals worth $407K as of Q1 2026.
  • Susquehanna International Group sold 83 Tonix Pharmaceuticals shares in Q1 2026, an estimated $1.28K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10166 holding.
  • Susquehanna International Group first reported a position in Tonix Pharmaceuticals in Q1 2021 and has held it in 5 quarters since.
  • Susquehanna International Group's Tonix Pharmaceuticals position peaked at $1.01M in Q1 2021.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.